According to the Dongwu Securities Research Report, Borui Pharmaceutical's IND application for BGM0504 tablets of the dual-target GLP-1/GIP receptor agonist has been accepted. Data on injections are ahead, and oral administration also has BIC potential. Amylin has great potential and a good competitive landscape, and the company's pipeline has potential for joint use. BGM1812 is a long-acting insulin analog that is currently in the preclinical stage. Currently, the only amylin drug on the market is AstraZeneca's pramlintide. It has only been approved for diabetes, and weight loss is in phase 2 clinical trials. BGM1812 can be used in conjunction with the company's existing BGM0504, with reference to cagrisema, which is expected to achieve better efficacy and collaboration within the company's products. Considering the gradual entry of the company pipeline into the clinical phase and the increase in certainty, the company's rating was raised to a “buy” rating.

According to the Dongwu Securities Research Report, Borui Pharmaceutical's IND application for BGM0504 tablets of the dual-target GLP-1/GIP receptor agonist has been accepted. Data on injections are ahead, and oral administration also has BIC potential. Amylin has great potential and a good competitive landscape, and the company's pipeline has potential for joint use. BGM1812 is a long-acting insulin analog that is currently in the preclinical stage. Currently, the only amylin drug on the market is AstraZeneca's pramlintide. It has only been approved for diabetes, and weight loss is in phase 2 clinical trials. BGM1812 can be used in conjunction with the company's existing BGM0504, with reference to cagrisema, which is expected to achieve better efficacy and collaboration within the company's products. Considering the gradual entry of the company pipeline into the clinical phase and the increase in certainty, the company's rating was raised to a “buy” rating.